OBJECTIVE -The purpose of this study was to estimate the longitudinal variation of prevalence of metabolic syndrome within French families and to observe biological parameters involved in cardiovascular disease among their offspring.
T
oday there is growing interest in a cluster of synergistically interacting cardiovascular risk factors called "metabolic syndrome" (or "insulin resistance syndrome"), which is mainly characterized by insulin resistance, glucose intolerance, dyslipidemia, hypertension, and obesity (1) . In fact, this syndrome, which affects one-quarter of the American population, may have serious consequences for cardiovascular disease (CVD) and diabetes development (2) . The European population is also concerned about metabolic syndrome, as indicated by the European Group for the Study of Insulin Resistance (3) . However, limited information is available about the prevalence of metabolic syndrome in Europe, particularly in France.
The French STANISLAS cohort, which was set up to study the role and contribution of genetic and environmental factors in the variability of cardiovascular risk factors (4) , has some advantages for understanding metabolic syndrome. First, because the STANISLAS cohort is a longitudinal study, it can be used to assess how metabolic syndrome prevalence varies with age. Second, the individuals involved in this study are from homogenous origin (French origin for two generations). Therefore, our results will not be biased and will be specific for our population because it has been shown that metabolic syndrome varies substantially by ethnicity, even after adjustments for BMI, age, socioeconomic status, and other predictor variables (5) . The estimation of metabolic syndrome prevalence in the Third National Health and Nutrition Examination Survey (NHANES III) for U.S. adults was found to differ between ethnic groups (2) . Ethnic heterogeneity was also observed elsewhere (6, 7) . Third, these individuals are presumably healthy, with no familial history of CVD. The prevalence of metabolic syndrome in people suffering from different pathologic conditions was much higher than in control subjects. In a cohort of patients suffering from atherosclerotic CVD, it was 46% (and 41% in coronary artery disease patients) (8) . In type 2 diabetes patients, it was 63.2% according to the National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP) definition and 81.1% according to the World Health Organization definition (9) . Drug treatment has also been shown to have an effect on metabolic syndrome prevalence. A study in patients treated by antihypertensive drugs revealed a prevalence that varied from 0.8 to 35.5%, depending on the definition used (10) .
Finally, this study consists of families. Many studies have suggested that offspring of subjects with metabolic syndrome are potential targets for developing the syndrome because of its familial aggregation (11) (12) (13) . Therefore, in this article, we assessed the prevalence of metabolic syndrome among supposedly healthy families of the STANISLAS cohort over a 5-year period. Moreover, in this familial context, we sought to determine how CVD risk factors vary in children of parents with metabolic syndrome.
RESEARCH DESIGN AND
METHODS -The STANISLAS cohort is a 10-year family study. Its main objective is to investigate the impact of genetic and environmental factors on the variability of cardiovascular risk factors (4, 14) . Recruitment of families from Northeastern France started in 1993 (t 0 ) by an invitation for a health examination in the Center for Preventive Medicine at Vandoeuvre-lè s-Nancy. At this time, 1,006 presumably healthy families (4,295 individuals) were recruited and responded to the following selection criteria: families of French origin, consisting of two parents and at least two biological children aged 4 or more, with members of the family free from serious and/or chronic illnesses. All participants gave their written informed consent. This cohort was approved by the Local Ethics Committee of Nancy, France. In 1998 (t ϩ5 ), the participants came back for the second health screening, with a participation rate of 75%.
In this study, we investigated 371 nuclear families present at both visits, with at least one child aged Յ20 years. They consisted of 371 fathers, 371 mothers, 282 sons, and 313 daughters. Children Ͼ20 years old were excluded to avoid the influence of age on the studied variables. The subjects were present at t 0 and t ϩ5 and were selected according to the following criteria: glucose Յ8 mmol/l, apolipoprotein (apo) E Յ200 mg/l, cholesterol or triglycerides Յ10 mmol/l, orosomucoid or haptoglobulin Յ3 g/l, C-reactive proteins Յ30 mg/l, and aspartate aminotransferase or alanine aminotransferase activities Յ200 units/l. At a second time point, we stratified our study and considered only individuals who did not take the following drug treatments: antiangina drugs, antihypertensive drugs, antiarythmics, cardiotonics and cardiac analeptics, vasodilatators, antidiabetic drugs, lipidlowering drugs, diuretics, and antiinflammatory drugs. The population was then composed of 256 fathers, 296 mothers, 265 sons, and 286 daughters.
According to NCEP ATP criteria (15), a participant has metabolic syndrome if he or she has three or more of the following criteria: waist circumference Ͼ102 cm in men and Ͼ88 cm in women; triglyceride levels Ն1.70 mmol/l; HDL cholesterol concentration Ͻ1.04 mmol/l in men and Ͻ1.30 mmol/l in women; blood pressure Ն130/85 mmHg; and fasting glucose value Ն6.1 mmol/l. Metabolic syndrome was calculated according to the following three different interpretations of the NCEP ATP definition (D): D1 does not take drugs into account; D2 includes antihypertensive drugs; and D3 includes all drugs that treat metabolic syndrome-related abnormalities (i.e., antihypertensive, lipidlowering, and antidiabetic drugs).
Evaluation of clinical characteristics
Data dealing with tobacco, alcohol, weight at birth, size at birth, current use of 
Biochemical measurements
Blood samples were taken from subjects after an overnight fast. Venous blood was collected without anticoagulant in Vacutainer tubes (Becton Dickinson, Rutherford, NJ) containing a gel for serum separation. These samples were centrifuged at 1,000g for 15 min at room temperature and were analyzed for all constituents except apoCIII and insulin concentrations. Serum aliquots were stored in 250-l straws in liquid nitrogen at Ϫ196°C before being analyzed for these two last constituents. HDL cholesterol was assayed after precipitation of other lipoproteins with phosphotungstate-magnesium on the COBAS-Mira analyzer (Roche Diagnostics, Basel, Switzerland), and total cholesterol, as well as glucose and triglycerides, was assessed enzymatically with an AU 640 automated device (Olympus, Rungis, France). Current values of fasting serum insulin concentration were evaluated by a Microparticular Enzymatic ImmunoAssay on an IMx Abbott automated device (Abbott Laboratories, Abbott Park, IL). The method and reference values for the STANISLAS cohort have already been detailed elsewhere (16) . LDL cholesterol was calculated from Friedewald's formula. Serum apoA1 and apoB as well as n ϭ 371 fathers and 371 mothers for D1, D2, and D3, and n ϭ 256 fathers and 256 mothers for prevalence. Prevalence represents the prevalence of the metabolic syndrome among men and women of the STANISLAS cohort without medication and was assessed according to three different interpretations of the NCEP ATP definition as follows: D1 does not take drugs into account (this is the definition given by the NCEP); D2 includes antihypertensive drugs; and D3 includes all drugs treating metabolic syndrome-related abnormalities.
haptoglobulin, orosomucoid, and C-reactive protein concentrations were measured by immunonephelometry with a Behring Nephelemeter Analyzer II (Dade Behring, Marburg, Germany). Serum apoE and apoCIII concentrations were assessed by immunoturbidimetry with a COBAS-Mira analyzer with Daïchi reagents. Lastly, interleukin-6 and tumor necrosis factor-␣ (TNF-␣) were measured in plasma with commercially available enzyme-linked immunosorbent assay (R&D System, Abington, U.K.) in samples stored in liquid nitrogen until use.
Statistical methods
Statistical analyses were performed with the SAS package program version 8.2 (SAS Institute, Cary, NC). Data for BMI, waist circumference, triglycerides, LDL lipoprotein cholesterol, HDL cholesterol, apoE, insulin, haptoglobin, orosomucoid, interleukin-6, and TNF-␣ concentrations were log-transformed to reduce skewing. Descriptive statistics were computed with means and SD for continuous measurements. Crude prevalence was determined at t 0 and t ϩ5 as the frequency of men and women presenting metabolic syndrome as defined by the NCEP ATP.
Biological parameter values were compared among offspring of parents who had or currently have metabolic syndrome versus age-and sex-matched control subjects (children with parents without metabolic syndrome) by ANOVA tests. These control subjects were randomly chosen. Because individuals within a family are not independent, ANOVA tests were performed by an SAS GENMOD procedure with a family factor as a repeated statement. GENMOD is based on the generalized estimating equation (17) . P Ͻ 0.05 was regarded as statistically significant.
RESULTS -Clinical and metabolic characteristics of our studied population at t 0 are summarized in Table 1 . As shown in Table 2 , the prevalence of metabolic syndrome increased over the 5-year interval (t 0 to t ϩ5 ) and was higher in men than in women. It rose from 5.9 to 7.2% in men and from 2.1 to 5.4% in women (with D1). Moreover, 40.9% of men and 50% of women with the diagnosis of metabolic syndrome at t 0 also had the diagnosis of metabolic syndrome at t ϩ5 . Global incidence at 5 years for metabolic syndrome was 5.2 and 4.4% in men and women, respectively. Compared with the D2 or D3 definition, prevalence was higher when the D1 definition was used. In addition, we observed that if we excluded individuals under drug treatment from our study, the prevalence was reduced to 3.5% at t 0 and to 4.7% at t ϩ5 in men and to 1% at t 0 and to 4.4% at t ϩ5 in women. Figure 1 presents the distribution of metabolic syndrome criteria among fathers and mothers according to D1, D2, and D3 definitions and in fathers and mothers without any drug treatment.
Our data showed that whichever NCEP ATP definition was used, the characteristics mainly found at both t 0 and t ϩ5 in the individuals affected by metabolic syndrome were elevated blood pressure and hypertriglyceridemia in men and abdominal obesity (increased waist circumference), low HDL cholesterol, and hypertension in women. For instance, when D1 was applied to men at t 0 , 90.9% (92.6% at t ϩ5 ) had elevated blood pressure and 95.5% had hypertriglyceridemia. Of women at t 0 , 87.5% (75% at t ϩ5 ) had low HDL cholesterol levels, 75% (85% at t ϩ5 ) had abdominal obesity, and 100% had elevated blood pressure (70% at t ϩ5 ). Hyperglycemia was the less frequent risk factor for metabolic syndrome in both men and women (data not shown).
The investigation of potential clinical (Table 3) and biological (Table 4 ) risk factors for CVD in the children of parents who had or currently have metabolic syndrome defined by D1 gave the following results: TNF-␣ concentrations were significantly higher (P ϭ 0.009), whereas HDL cholesterol at t 0 (P ϭ 0.03) and apoE concentrations at t 0 (P ϭ 0.03) and t ϩ5 (P ϭ 0.05) were significantly lower in children of parents with metabolic syndrome than in age-and sex-matched control subjects. Additionally, insulin Values of the clinical characteristics of metabolic syndrome are considered in children (7-20 years old). Children of parents with metabolic syndrome (D1) are assessed versus age-and sex-matched control subjects (children of parents without metabolic syndrome). Adjustments for sex were performed. PMS: at least one parent has or has had metabolic syndrome; age-and sex-matched control subjects: no parent has or has had metabolic syndrome. D1 corresponds to the NCEP ATP definition of metabolic syndrome including abdominal obesity, hypertriglyceridemia, low HDL cholesterol, hypertension, and hyperglycemia; D3 additionally includes antihypertensive drugs, lipid-lowering drugs, and antidiabetic drugs. *P values are presented for D3 (n ϭ 112 in both PMS and control samples); †parameters considered in the NCEP ATP definition of metabolic syndrome; ‡P Ͻ 0.05.
concentration was higher in children of parents with metabolic syndrome than in control subjects (P ϭ 0.05). The same comparison study was performed by applying the D2 and D3 definitions. Only significant results with D3 definitions are shown (Tables 3 and 4) . Moreover, we have tested the influence of alcohol, exercise, and smoking on the concentration of HDL cholesterol. No influence of exercise and smoking was found. On the other hand, we observed a significant interaction between alcohol consumption and parental metabolic syndrome on HDL cholesterol concentration with D1 (P ϭ 0.009), D2 (P ϭ 0.004), and D3 (P ϭ 0.0015). This could be tested only at t ϩ5 because the number of children who drank at t 0 was not sufficient (Table 4) . Our result showed that, given a daily quantity of alcohol consumed, a child with a parent who has metabolic syndrome has an HDL cholesterol concentration lower than that of a matched control subject. In any case, children who drink alcohol have higher HDL cholesterol concentrations than nondrinkers. The CVD markers that showed statistical significance when either D1, D2, or D3 definitions were applied are summarized in Fig. 2 . In this graphical representation, each circle corresponds to a version of metabolic syndrome definition (D1, D2, or D3 definitions). The intersection of these three circles permitted us to see that among all factors, HDL cholesterol, TNF-␣, and the interaction between alcohol consumption and parental metabolic syndrome on HDL cholesterol were significant among the three comparison studies.
CONCLUSIONS -In this article, we
give a first estimate of the prevalence of metabolic syndrome in the STANISLAS cohort according to NCEP ATP criteria. We took care to compare our results only with results from the literature that were produced according to NCEP ATP criteria because some discrepancies have been observed depending on the definition chosen. The NCEP ATP definition of metabolic syndrome was chosen rather than the World Health Organization or European Group for the Study of Insulin Resistance criteria because it relies on variables that are easily ascertainable by physicians and thus is convenient operationally (18) .
The NHANES III study of metabolic syndrome involving 4,265 men and 4,549 women observed metabolic syndrome frequencies of 24.0 and 23.4% in Data are means Ϯ SD, unless otherwise indicated. Values of the biomarker measurements considered in metabolic syndrome among offspring up to 20 years old (7-20 years). Children of parents with metabolic syndrome (D1) are assessed versus age-matched and sex-matched controls (with parents without metabolic syndrome). Adjustments for sex were performed. PMS: at least one parent has or has had metabolic syndrome; age-matched and sex-matched controls, no parent has or has had MS. D1 corresponds to the NCEP ATP definition of metabolic syndrome including abdominal obesity, hypertriglyceridemia, low HDL cholesterol, hypertension, and hyperglycemia; D3 additionally includes antihypertensive drugs, lipid-lowering drugs, and antidiabetic drugs. PMS/control subjects effects for apoCIII, apoE, haptoglobin, orosomucoid, C-reactive protein, interleukin-6, and TNF-␣ when applying D3 definition were 26/56, 112/111, 19/54, 110/108, 109/108, 17/51, and 17/50, respectively. *n ϭ 112 for both PMS and control samples; †parameters considered in the NCEP ATP definition of metabolic syndrome; ‡P Յ 0.05; §P Յ 0.01; ¶interaction on HDL cholesterol with alcohol by parent with metabolic syndrome; ʈP Յ 0.001.
American men and women, respectively (2). Among Framingham Offspring Study white subjects, the NCEP ATP prevalence was 24% and among San Antonio Heart Study white subjects, it was 23% (6). Therefore, the American prevalence is globally sixfold higher than in the STANISLAS cohort at t 0 . However, the gap is progressively reduced because at t ϩ5 the American prevalence is about fourfold higher. Importantly, even when assessing healthy adults without medication, we observed that metabolic syndrome was incontestably present. The French DESIR (Data from an Epidemiological Study on the Insulin Resistance Syndrome) study, which included volunteers from central-western France, observed that at baseline, 10% of men and 7% of women had metabolic syndrome compared with 5.9% of men and 2.1% of women in our population (19) . Age ranges were comparable between DESIR and our study.
We found that 40.9% of men and 50% of women (D1 definition) had this syndrome at baseline and at 5 years. In the French DESIR study, only 12 and 8%, respectively, had metabolic syndrome at baseline and at 3 years (19) .
Age-adjusted characteristics of the different populations described above are compared with those of the STANISLAS cohort, shown in Table 5 . The differences in these characteristics can be explained by differences in age, geographical regions, and selection methods. Here, our results are in agreement with those obtained in DESIR.
Our results confirm the wellestablished increase in metabolic syndrome with age and that metabolic syndrome is generally more prevalent in men than in women (21) . In our study, metabolic syndrome prevalence has increased by ϳ3 points in 5 years (Table 2) .
In our population, we found that elevated blood pressure and hypertriglyceridemia in men and abdominal obesity and hypertension in women were the more frequent criteria. Hypertension was also the criteria more present in the French DESIR (19) and MONICA (Monitoring Cardiovascular Disease) (21) studies. Central obesity is the first criteria in the U.S. (2).
We observed that HDL cholesterol and TNF-␣ concentrations were the two parameters that were significantly different among children of parents with metabolic syndrome and control children when we compared results obtained with three different interpretations of the NCEP ATP definition involving or not involving some specific medication related to the criteria considered for diagnosing metabolic syndrome. To our knowledge, this is the first time that such an investigation was performed in a French population. The only investigation we found presenting a similar scheme was performed by Pankow et al. in an American population (22) . However, this study did not analyze as many lipid parameters as we did and did not investigate inflammatory molecules at all. These authors found a significantly higher insulin concentration and higher parameters for obesity (including waist circumference and waist-to-hip ratio) in children of parents with metabolic syndrome. Similar associations, although not consistently significant, were observed in our study using the three definitions D1, D2, and D3 (see Fig.  2 ). Pankow et al. found no significant differences in the lipid levels that they investigated, including HDL cholesterol. On the contrary, in our study, HDL cholesterol was lower and TNF-␣ was higher in children of parents with metabolic syndrome than in control subjects, and this was consistently found by applying the three definitions. Low HDL cholesterol is known as a risk factor for coronary artery disease in adults (23, 24) . It is considered to be an important parameter of metabolic syndrome in adults because it is included in the three major definitions proposed at this time (15, 25, 26) . In our study, it appears to be an important factor to follow during childhood. Additionally, we reported an interaction by using D1, D2, and D3 definitions, consisting of a significantly less important alcohol-related HDL cholesterol increase in children of parents with metabolic syndrome compared with control subjects. It is well known that alcohol intake leads to an increase in HDL cholesterol (27, 28) . Moreover, it has been suggested that metabolic syndrome is negatively associated with light alcohol consumption in middleaged Korean adults (29) . However, the mechanism by which parental metabolic syndrome acts on HDL cholesterol ho- meostasis in children who drink alcohol remains to be elucidated.
The proinflammatory cytokine TNF-␣ has been implicated in insulin resistance (30) . It has also been suggested to be a cardiovascular risk factor (31) . Levels fourfold higher were observed in insulinresistant obese humans compared with healthy humans (32) . Obese adolescents have been shown to exhibit higher TNF-␣ and its soluble receptor concentrations than nonobese ones, and TNF-␣ concentration has been positively correlated with several components of metabolic syndrome in obese adolescents (33) . These results suggest that this cytokine could be an early marker of the inflammatory state predisposing to metabolic syndrome development during childhood. Therefore, low HDL cholesterol and TNF-␣ may play an important role in the development of metabolic syndrome in childhood, at least in our population. These two parameters deserve specific attention as targets for prevention and treatment.
We are aware of some limitations to our study. Although the STANISLAS cohort consists of individuals who were apparently in good health at their inclusion in the study, we cannot exclude the possibility that silent CHD could have been present in some subjects; however, none of the tests and questionnaires collected supported such occurrences. Moreover, as indicated by its inclusion criteria (see RESEARCH DESIGN AND METHODS), the STANI-SLAS cohort is not a group representative of the French population. All the individuals enrolled are insured by French Social Security (covering Ͼ80% of the French population). They were invited to the Centre for Preventive Medicine for a health check-up at Vandoeuvre-lè sNancy (France) and agreed to participate in a 10-year study and to come back for a medical examination every 5 years.
However, describing metabolic syndrome in such a group is interesting because it shows that this disorder can be isolated even in a healthy cohort and that more significant differences appear in the offspring of presumably healthy individuals affected by metabolic syndrome.
Our results suggest that metabolic syndrome occurs insidiously, even in healthy individuals. Moreover, our study results underline the importance of early management of children of parents with metabolic syndrome to prevent obesity, which is more and more frequent in childhood and is clearly a serious aggravating circumstance for development of metabolic syndrome, type 2 diabetes, and CVD in adulthood.
The NCEP ATP is perhaps not the best definition for the STANISLAS cohort.
Nevertheless, it has the advantage of enabling the detection of metabolic syndrome, even in a healthy cohort. At present, there are no well-accepted criteria for diagnosing metabolic syndrome. A more age-sex-ethnic geographic definition is required, including guidelines that would be recognized worldwide. In this context, the understanding of metabolic syndrome mechanisms in a familial healthy population would be of interest. Therefore, one purpose of our cohort should be to further the establishment of metabolic syndrome reference values for the French and European populations. Data are %, unless otherwise indicated. Prevalence of characteristics involved in NCEP-defined MS among population samples from STANISLAS, NHANES III, the Framingham Offspring Study (FOS), the San Antonio Heart Study (SAHS), and the DESIR cohort study. Data for central obesity are also provided. *Data at inclusion examination. Data are age-standardized frequencies for the French population in 1999; †age-adjusted prevalence of individual metabolic abnormalities in metabolic syndrome. Age adjustment was performed using the age distribution of the U.S. population in the year 2000; ‡data are age-adjusted percentages using logistic regression; §data refer to a sample of 3,500 white individuals (20) ; ¶data refer to a sample of 7,323 individuals (3).
